BXMPY (Beximco Pharmaceuticals) General and Admin. Expense: $11.72 Mil (TTM As of Mar. 2026)


What is Beximco Pharmaceuticals General and Admin. Expense?

Beximco Pharmaceuticals BXMPY 68 General and Admin. Expense is $11.72 Mil as of Mar. 2026. GuruFocus rates BXMPY with a GF Score™ of 68/100. The stock has 6 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Beximco Pharmaceuticals's General and Admin. Expense for the three months ended in Mar. 2026 was $3.10 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $11.72 Mil.

Beximco Pharmaceuticals General and Admin. Expense Related Terms

Beximco Pharmaceuticals General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Beximco Pharmaceuticals's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beximco Pharmaceuticals General and Admin. Expense Chart

Beximco Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.56 5.25 5.42 5.79 7.59

Beximco Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.75 2.51 2.88 3.23 3.10

Beximco Pharmaceuticals General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of $11.72 Mil mean?
Beximco Pharmaceuticals (BXMPY) has a General and Admin. Expense of $11.72 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Beximco Pharmaceuticals and its competitors.
Is Beximco Pharmaceuticals' General and Admin. Expense too high?
Beximco Pharmaceuticals' current General and Admin. Expense is $11.72 Mil. Overall, Beximco Pharmaceuticals has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' General and Admin. Expense compare to ZTS and UTHR?
Beximco Pharmaceuticals' General and Admin. Expense of $11.72 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Drug Manufacturers company?
A good General and Admin. Expense depends on the Drug Manufacturers industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Beximco Pharmaceuticals and its competitors. Beximco Pharmaceuticals's current General and Admin. Expense is $11.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Beximco Pharmaceuticals (BXMPY) has a current General and Admin. Expense of $11.72 Mil. The current General and Admin. Expense is $11.72 Mil. Beximco Pharmaceuticals' overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Beximco Pharmaceuticals (BXMPY), the current General and Admin. Expense is $11.72 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beximco Pharmaceuticals Business Description

Address 19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.